Institutional members access full text with Ovid®

Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa

Mosam, Anisaa; Cassol, Edanab; Page, Tarynb; Bodasing, Uvanic; Cassol, Sharonb; Dawood, Halimad; Friedland, Gerald He; Scadden, David Tf; Aboobaker, Jamilaa; Jordaan, Jacobus Pg; Lalloo, Umesh Gd; Esterhuizen, Tonya Mh; Coovadia, Hoosen Mi

Research Letters

Generic antiretroviral drugs are pivotal in the implementation of WHO's ‘3 by 5’ programme. However, clinical experience with generics in sub-Saharan Africa is insufficiently documented. We report on 50 patients with HIV-associated Kaposi's sarcoma treated with generic fixed-dose highly active antiretroviral therapy. At 52 weeks, 74% achieved an undetectable viral load of < 50 copies/ml, 86% achieved < 400 copies/ml, and a 3.1 log10 decline from baseline. Side-effects were minimal. The outcomes support the use of generic antiretroviral therapy.

Departments of aDermatology

bMolecular Virology and Bioinformatics, Africa Centre for Health and Population Studies, Durban, South Africa

cCentre for HIV/AIDS Networking

dDepartment of Infectious Diseases

eAIDS Programme, Yale University School of Medicine, New Haven, CT, USA

fDepartment of Haematologic Malignancies, MGH Cancer Center, Harvard Medical School, Cambridge, MA, USA

gDepartment of Oncology and Radiotherapy

hMedical Bioethics Unit

iVictor Daitz Chair of HIV/AIDS Research, Faculty of Health Sciences, Nelson R. Mandela School of Medicine, University of KwaZulu, Natal, South Africa.

Received 25 November, 2004

Accepted 23 December, 2004

© 2005 Lippincott Williams & Wilkins, Inc.